NI201800042A - Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 - Google Patents
Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1Info
- Publication number
- NI201800042A NI201800042A NI201800042A NI201800042A NI201800042A NI 201800042 A NI201800042 A NI 201800042A NI 201800042 A NI201800042 A NI 201800042A NI 201800042 A NI201800042 A NI 201800042A NI 201800042 A NI201800042 A NI 201800042A
- Authority
- NI
- Nicaragua
- Prior art keywords
- dyrk1
- pirrolo
- clk1
- pyrimidine
- new derivatives
- Prior art date
Links
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 title 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 title 1
- 101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 title 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(Fórmula I) Compuestos de fórmula (I): útiles para el tratamiento de cáncer, trastornos neurodegenerativos y trastornos metabólicos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1559259A FR3041640B1 (fr) | 2015-09-30 | 2015-09-30 | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201800042A true NI201800042A (es) | 2018-06-21 |
Family
ID=54979756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201800042A NI201800042A (es) | 2015-09-30 | 2018-03-23 | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20180273538A1 (es) |
| EP (1) | EP3356364A1 (es) |
| JP (1) | JP2018533552A (es) |
| KR (1) | KR20180054856A (es) |
| CN (1) | CN108137582A (es) |
| AU (1) | AU2016333508A1 (es) |
| BR (1) | BR112018005851A2 (es) |
| CA (1) | CA2999937A1 (es) |
| CL (1) | CL2018000786A1 (es) |
| CO (1) | CO2018003466A2 (es) |
| CR (1) | CR20180176A (es) |
| CU (1) | CU20180027A7 (es) |
| DO (1) | DOP2018000082A (es) |
| EA (1) | EA201890820A1 (es) |
| EC (1) | ECSP18023286A (es) |
| FR (1) | FR3041640B1 (es) |
| HK (1) | HK1255467A1 (es) |
| IL (1) | IL258231A (es) |
| MA (1) | MA43021A (es) |
| MX (1) | MX2018003861A (es) |
| NI (1) | NI201800042A (es) |
| PE (1) | PE20190337A1 (es) |
| PH (1) | PH12018500605A1 (es) |
| SV (1) | SV2018005656A (es) |
| TN (1) | TN2018000087A1 (es) |
| WO (1) | WO2017055533A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR102054910B1 (ko) * | 2017-12-19 | 2019-12-12 | 한림제약(주) | 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| CA3118093A1 (en) * | 2018-09-28 | 2020-04-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1/clk and uses thereof |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| AR120799A1 (es) * | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr |
| WO2022117012A1 (zh) * | 2020-12-02 | 2022-06-09 | 百极弘烨（广东）医药科技有限公司 | 螺环jak抑制剂、含其的药物组合物及其应用 |
| US20240261297A1 (en) * | 2021-05-20 | 2024-08-08 | St. John's Cancer Institute | Anti-cdk inhibitors for cancer treatment |
| UY39979A (es) | 2021-10-12 | 2023-04-14 | Biosplice Therapeutics Inc | Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas |
| CA3234937A1 (en) * | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors |
| US20230192686A1 (en) * | 2021-10-12 | 2023-06-22 | Biosplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines and preparation and uses thereof |
| WO2023110843A1 (en) * | 2021-12-15 | 2023-06-22 | Almirall, S.A. | Heterobicyclic derivatives as itk inhibitors |
| CN116621843B (zh) * | 2022-06-13 | 2024-05-24 | 四川大学华西医院 | 一种dna甲基转移酶1抑制剂及其制备方法和用途 |
| CN115785134B (zh) * | 2022-10-28 | 2023-08-29 | 浙大城市学院 | 一种含氮杂环的硼酸化合物及制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101378716B1 (ko) | 2005-05-20 | 2014-04-10 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제 |
| US20080004295A1 (en) | 2005-10-13 | 2008-01-03 | Gore Paul M | Novel compounds |
| EA200801968A1 (ru) | 2006-03-11 | 2009-02-27 | Вернэлис (Р&Д) Лтд. | Пирролопиримидиновые производные, используемые в качестве ингибиторов hsp90 |
| FR2912744B1 (fr) * | 2007-02-16 | 2012-09-07 | Centre Nat Rech Scient | Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations. |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| EP3255049A1 (en) * | 2012-06-29 | 2017-12-13 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| EP3083618B1 (en) * | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
-
2015
- 2015-09-30 FR FR1559259A patent/FR3041640B1/fr not_active Expired - Fee Related
-
2016
- 2016-09-30 MA MA043021A patent/MA43021A/fr unknown
- 2016-09-30 HK HK18114640.5A patent/HK1255467A1/zh unknown
- 2016-09-30 PE PE2018000410A patent/PE20190337A1/es unknown
- 2016-09-30 EP EP16774684.1A patent/EP3356364A1/en not_active Withdrawn
- 2016-09-30 US US15/763,626 patent/US20180273538A1/en not_active Abandoned
- 2016-09-30 WO PCT/EP2016/073403 patent/WO2017055533A1/en not_active Ceased
- 2016-09-30 EA EA201890820A patent/EA201890820A1/ru unknown
- 2016-09-30 TN TNP/2018/000087A patent/TN2018000087A1/en unknown
- 2016-09-30 CA CA2999937A patent/CA2999937A1/en not_active Abandoned
- 2016-09-30 KR KR1020187012166A patent/KR20180054856A/ko not_active Withdrawn
- 2016-09-30 BR BR112018005851A patent/BR112018005851A2/pt not_active Application Discontinuation
- 2016-09-30 CN CN201680058179.3A patent/CN108137582A/zh not_active Withdrawn
- 2016-09-30 JP JP2018516488A patent/JP2018533552A/ja active Pending
- 2016-09-30 CR CR20180176A patent/CR20180176A/es unknown
- 2016-09-30 AU AU2016333508A patent/AU2016333508A1/en not_active Abandoned
- 2016-09-30 CU CUP2018000027A patent/CU20180027A7/es unknown
- 2016-09-30 MX MX2018003861A patent/MX2018003861A/es unknown
-
2018
- 2018-03-19 IL IL258231A patent/IL258231A/en unknown
- 2018-03-20 PH PH12018500605A patent/PH12018500605A1/en unknown
- 2018-03-22 SV SV2018005656A patent/SV2018005656A/es unknown
- 2018-03-23 NI NI201800042A patent/NI201800042A/es unknown
- 2018-03-26 CL CL2018000786A patent/CL2018000786A1/es unknown
- 2018-03-26 EC ECIEPI201823286A patent/ECSP18023286A/es unknown
- 2018-03-26 DO DO2018000082A patent/DOP2018000082A/es unknown
- 2018-03-28 CO CONC2018/0003466A patent/CO2018003466A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201890820A1 (ru) | 2018-10-31 |
| TN2018000087A1 (en) | 2019-07-08 |
| PE20190337A1 (es) | 2019-03-07 |
| KR20180054856A (ko) | 2018-05-24 |
| EP3356364A1 (en) | 2018-08-08 |
| HK1255467A1 (zh) | 2019-08-16 |
| DOP2018000082A (es) | 2018-10-15 |
| CN108137582A (zh) | 2018-06-08 |
| MA43021A (fr) | 2018-08-08 |
| US20180273538A1 (en) | 2018-09-27 |
| IL258231A (en) | 2018-05-31 |
| CU20180027A7 (es) | 2018-07-05 |
| CO2018003466A2 (es) | 2018-07-10 |
| CL2018000786A1 (es) | 2018-09-28 |
| JP2018533552A (ja) | 2018-11-15 |
| BR112018005851A2 (pt) | 2018-10-09 |
| SV2018005656A (es) | 2018-08-10 |
| FR3041640A1 (es) | 2017-03-31 |
| CR20180176A (es) | 2018-05-31 |
| AU2016333508A1 (en) | 2018-04-12 |
| ECSP18023286A (es) | 2018-04-30 |
| MX2018003861A (es) | 2018-08-16 |
| WO2017055533A1 (en) | 2017-04-06 |
| CA2999937A1 (en) | 2017-04-06 |
| PH12018500605A1 (en) | 2018-09-24 |
| FR3041640B1 (fr) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| MX373786B (es) | Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer. | |
| MY184733A (en) | Pyrimidine fgfr4 inhibitors | |
| MX372997B (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CL2016001895A1 (es) | Compuestos | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| MX2016010571A (es) | Pirazolil-ureas como inhibidores de quinasas. | |
| CL2014002301A1 (es) | Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras. | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| MX2015000129A (es) | Derivados de pirimidin pirazolilo. | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| MX2015014298A (es) | Compuestos de dihidropirido pirimidina como inhibidores de autotaxina. | |
| NI201800043A (es) | Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1 | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| UY35274A (es) | Compuestos y métodos para tratar infecciones bacterianas | |
| WO2014113407A3 (en) | Use of small molecule inhibitors targeting eya tyrosine phosphatase | |
| JO3372B1 (ar) | مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية | |
| DK3083627T3 (da) | [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis | |
| MX2016004841A (es) | Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk). | |
| MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы |